As well as the treatment of stroke 41 and myocardial infarction 42, the use of recombinant ADAMTS‐13 as a replacement therapy in acquired TTP 47 and the possibility of gene therapies to overcome ADAMTS‐13 deficiency 48 are also being investigated. This evidence concerns the gene ADAMTS13 and thrombotic thrombocytopenic purpura.